Clinical Study
Systemic Lymphadenectomy Cannot Be Recommended for Low-Risk Corpus Cancer
Table 1
Patients characteristics ().
| ||||||||||||||||||||||||||||||||||||||||
WHO*: World Health Organization, FIGO**: International Federation of Gynecology and Obstetrics Paclitaxel/carboplatin §: Paclitaxel (180 mg/m2) and carboplatin (area under the curve; AUC 5). |